Goldman Sachs Maintains Buy on Beta Bionics, Raises Price Target to $19

Benzinga · 1d ago
Goldman Sachs analyst David Roman maintains Beta Bionics (NASDAQ:BBNX) with a Buy and raises the price target from $17 to $19.